Navigation Links
Acid Test - Glaxo's Cervarix, and Merck's Gardasil, Compete

GlaxoSmithKline Plc, Europe's pharmaceutical giant, is finalizing its plan of action, to test its experimental// vaccine Cervarix against Merck & Co.'s Gardasil, in a bid to establish the most effective vaccine against cervical cancer.

The study, which will be conducted in the United States, will seek to evaluate the immune responses of women aged 18 to 26 years old, to two strains of the human papillomavirus. This virus is known to be the reason behind 70 percent of cervical cancers.

Glaxo has presented Cervarix to European regulators, while Gardasil received approval in the U.S. and Europe in 2006. Analyst Tim Anderson of Prudential Equity Group said, ``this is a very strategic and high stakes gamble by Glaxo that could have significant implications for both companies.''

Statistics show that cervical cancer is the second-most common cancer among women, with as many as 250,000 women dying every year to the disease. Both the vaccines in question comprise of vaccine boosters called adjuvants. Merck's Gardasil utilizes a conventional aluminum adjuvant, while Glaxo's Cervarix, uses a proprietary adjuvant named as AS04. Glaxo is confident of AS04’s effectiveness and that’s why the trial.

Brian Lortie, Glaxo's vice president of operations for the vaccine, said, ``we as a company think that the adjuvants differentiate the company. These are always risks that you take in clinical trials. We think there are some fundamental differences between these vaccines and that's why we're confident to begin the trial.''

Glaxo has decided to make the results of the trial public, irrespective of the brand that turns out to be the winner.


SA
'"/>




Page: 1

Related medicine news :

1. Daronrix, Glaxos Bird-flu Vaccine Approved by European Medicines Agency
2. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
3. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
4. Gardasil, a cervical cancer vaccine, hits the market
5. Botox Can Be a Competent Painkiller
6. Generic Products Compete With GlaxoSmithKline
7. Official Criticized For Not Recognizing the Competence of the Consultant Radiologist
8. Indian Americans Compete for the Prestigious Spelling Bee Contest
9. Two cloned mules, Compete In A Professional Race For The First Time Ever.
10. Sleep Deprivation can Affect Competent Decision-making
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... gender, and geographic lines. The goal of Castlewood Treatment Centers has always been ... accessible to as many people as possible. In that spirit, Castlewood has ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Spain Glaucoma Surgery Devices Market Outlook to ... Surgery Devices Market Outlook to 2022", provides key market ... report provides value, in millions of US dollars, volume ... - Canaloplasty Micro Catheters and Glaucoma Drainage Devices. ... data for each of these market segements, and global ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Cornerstone ... company, today presented data from two Phase I ... sessions at the 58th annual meeting of the ... San Diego, California . The two datasets ... with acute myeloid leukemia (AML) and T-cell non-Hodgkin,s ...
(Date:12/5/2016)... 5, 2016  Pennsylvania Physician General Dr. Rachel ... Gary Tennis today filled prescriptions for naloxone, ... in York to demonstrate how ... Levine as a prescription to acquire naloxone at any ... to remember that any Pennsylvanian can walk up to ...
Breaking Medicine Technology: